白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2015年
4期
231-233,244
,共4页
楼金星%陈惠仁%郭智%陈鹏%何学鹏%杨凯%张媛%刘晓东%刘兵
樓金星%陳惠仁%郭智%陳鵬%何學鵬%楊凱%張媛%劉曉東%劉兵
루금성%진혜인%곽지%진붕%하학붕%양개%장원%류효동%류병
培门冬酶%EPOCH方案%非霍奇金T细胞淋巴瘤%治疗结果
培門鼕酶%EPOCH方案%非霍奇金T細胞淋巴瘤%治療結果
배문동매%EPOCH방안%비곽기금T세포림파류%치료결과
Pegaspargase%EPOCH regimen%Non-Hodgkin's T-cell lymphoma%Treatment outcome
目的 观察EPOCH方案联合培门冬酶治疗复发难治性T细胞非霍奇金淋巴瘤(T-NHL)的疗效和不良反应.方法 收集北京军区总医院血液科2010年1月至2014年1月收治的15例经病理确诊的T-NHL患者,均为复发难治性,采用培门冬酶联合EPOCH方案化疗,具体方案为:依托白苷50 mg/m2,表柔比星12 mg/m2,长春新碱0.4 mg/m2,第1天至第4天;环磷酰胺750 mg/m2,第5天;培门冬酶每天2500U/m2,第6天;泼尼松60 mg/m2,第1天至第6天,21 d为1个周期,共进行2～8个周期.结果 15例中完全缓解4例(26.7％),部分缓解6例(40.0％),总有效率66.7％,全组患者中位生存期20个月(5～30个月),2年总生存率为46.6％.主要不良反应为肝损伤、骨髓抑制及凝血功能异常.结论 EPOCH方案联合培门冬酶治疗复发难治T-NHL疗效较好,不良反应较少,患者可耐受,值得临床进一步研究.
目的 觀察EPOCH方案聯閤培門鼕酶治療複髮難治性T細胞非霍奇金淋巴瘤(T-NHL)的療效和不良反應.方法 收集北京軍區總醫院血液科2010年1月至2014年1月收治的15例經病理確診的T-NHL患者,均為複髮難治性,採用培門鼕酶聯閤EPOCH方案化療,具體方案為:依託白苷50 mg/m2,錶柔比星12 mg/m2,長春新堿0.4 mg/m2,第1天至第4天;環燐酰胺750 mg/m2,第5天;培門鼕酶每天2500U/m2,第6天;潑尼鬆60 mg/m2,第1天至第6天,21 d為1箇週期,共進行2～8箇週期.結果 15例中完全緩解4例(26.7％),部分緩解6例(40.0％),總有效率66.7％,全組患者中位生存期20箇月(5～30箇月),2年總生存率為46.6％.主要不良反應為肝損傷、骨髓抑製及凝血功能異常.結論 EPOCH方案聯閤培門鼕酶治療複髮難治T-NHL療效較好,不良反應較少,患者可耐受,值得臨床進一步研究.
목적 관찰EPOCH방안연합배문동매치료복발난치성T세포비곽기금림파류(T-NHL)적료효화불량반응.방법 수집북경군구총의원혈액과2010년1월지2014년1월수치적15례경병리학진적T-NHL환자,균위복발난치성,채용배문동매연합EPOCH방안화료,구체방안위:의탁백감50 mg/m2,표유비성12 mg/m2,장춘신감0.4 mg/m2,제1천지제4천;배린선알750 mg/m2,제5천;배문동매매천2500U/m2,제6천;발니송60 mg/m2,제1천지제6천,21 d위1개주기,공진행2～8개주기.결과 15례중완전완해4례(26.7％),부분완해6례(40.0％),총유효솔66.7％,전조환자중위생존기20개월(5～30개월),2년총생존솔위46.6％.주요불량반응위간손상、골수억제급응혈공능이상.결론 EPOCH방안연합배문동매치료복발난치T-NHL료효교호,불량반응교소,환자가내수,치득림상진일보연구.
Objective To observe the effect and toxicity of pegaspargase combined with EPOCH (P-EPOCH) regimen for patients with relapse and refractory non-Hodgkin' s T-cell lymphoma (T-NHL).Methods A total of 15 patients with pathologically diagnosed T-NHL from January 2010 to January 2014 of the Beijing Military Region General Hospital who had been treated with CHOP or CHOP-like regimens were relapse or refractory.They were treated by P-EPOCH regimen [VP16 50 mg/m2,E-ADM 12 mg/m2,VCR 0.4 mg/m2,dissolved in 500 ml saline sustained static drops 24 h on day 1 to 4;CTX 750 mg/m2,intravenous injection on day 5;pegaspargase 2 500 U ·m-2·d-1 given as intramuscular injection on day 6;oral prednisone 60 mg/m2 on day 1 to 6;21 days of a cycle].Results All the 15 patients were treated by P-EPOCH regimen.The response rate of the whole group was 66.7 ％,including CR 4 cases (26.7 ％) and PR 6 cases (40.0 ％).The median survival time was 20 months (5-30 months),and (2-year) overall survival rate was 46.6 ％.Main side effects were myelosuppression,liver dysfunction and disturbance of blood coagulation.Conclusion PEPOCH regimen is effective for patients with relapse and refractory T-NHL and has better tolerance,and worthy of clinical study.
